Keywords: NICE, Pfizer, Sutent, GIST

NICE backs use of sunitinib for the treatment of GISTs, but Pfizer to pay for first treatment cycle

Article | 23 September 2009

Print This

The UK’s National Institute for Health and Clinical Excellence (NICE), which advises on therapy options for England and Wales, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in